Premium
Effect of Conjugated Linoleic Acid (CLA) on Tumor Suppression in Canine Osteosarcoma Cells
Author(s) -
Wong Janice Y,
Park Yooheon,
Park Yeonhwa
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.lb501
Subject(s) - osteosarcoma , conjugated linoleic acid , apoptosis , cancer research , in vivo , cancer , linoleic acid , in vitro , cell culture , chemistry , biology , medicine , fatty acid , biochemistry , genetics
Cancer is one of the leading causes of death in the US both in men and women, second to the heart disease. Among types of cancer, osteosarcoma is the most common type of malignant bone cancer. Although there is substantial scientific research focusing on understanding mechanisms of osteosarcoma, the causes of osteosarcoma are largely unknown. One potential mechanism of osteosarcoma involves the non‐steroidal anti‐inflammatory drug‐activated gene 1 (NAG‐1), where NAG‐1 serves as the intermediate key regulator for tumor development and apoptosis for osteosarcoma. Conjugated linoleic acid (CLA) is a fatty acid with anticancer properties in vitro and in vivo studies that occurs naturally in many dairy and beef products. Thus the purpose of this study was to investigate the anticancer effects of CLA isomers on a canine osteosarcoma cell line, CLL 183. The trans ‐10, cis ‐12 CLA isomer effectively suppressed the tumor cell growth after 72 hour treatment, while the cis ‐9, trans ‐11 CLA isomer had no effect. Further experiments confirmed that the trans ‐10, cis ‐12 CLA isomer, but not the cis ‐9, trans ‐11 isomer, affects NAG‐1 expression. These results support our hypothesis that CLA's anticancer effects are in part mediated by controlling NAG‐1 expression.